369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

358: FDA's gene therapy turmoil, and an alternative model for funding research

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

354: Uncertainty in CRISPR world and the start of more M&A

353: Trump's drug-pricing plan and a potential Theranos 2.0

352: A firebrand takes oversight of vaccines, gene therapies

351: It's gonna be May (in biotech)

350: Pharma tariffs, and a 'sunshine day' for biotech stocks